Reliq Health Technologies

Core Capital Partners (formerly Hamza Thindal Capital Corp.) has been involved with Reliq Health Technologies (Formerly Moseda Technologies) since August 2015, with an initial investment of $500,000 and now an aggregate investment of over $2.5MM. Reliq is a Vancouver, BC based company focused on developing innovative software applications specifically designed as secure mobile healthcare solutions.

The Company is lead by Dr. Lisa Crossley. Dr. Crossley is an accomplished healthcare technology executive with a proven track record of successfully building and leading global tech companies. She has diverse experience across multiple market segments, including healthcare information technology, therapeutics, medical devices, life science tools and diagnostics.

In February 2016, Reliq acquired iUGO Health Inc. (formerly CareKit Health), a commercial stage healthcare technology company that has built a comprehensive hardware and software platform that allows complex patients to receive high quality care in the home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO platform for care coordination and home healthcare integrates wearables, sensors, a proprietary voice technology hub and intuitive mobile apps and desktop user interfaces for patients, clinicians and healthcare administrators.

More Recently, Reliq secured a paid pilot with Sacred Heart Hospital in Florida, US. The pilot will evaluate the use of Reliq’s iUGO Health platform to monitor patients post-discharge from hospital. The hub of the Sacred Heart system is its 566-bed Sacred Heart Hospital in Pensacola that includes the regions only Children’s Hospital, a Level II Trauma Center, a Cancer Center affiliated with MD Anderson Cancer Network and a Heart & Vascular Institute. Sacred Heart has more than 4,000 employees and is part of Ascension Health, the nation’s largest system of Catholic and non-profit health care facilities.


Vanc Pharmaceuticals

Core Capital Partners (formerly Hamza Thindal Capital Corp.) has been involved with Vanc Pharmaceuticals since 2012, with an initial co-investment of $800,000 and now an aggregate investment of $4.3MM over the past 24 months. Vanc is a Vancouver, BC based generic drug and OTC products company. The Company has partnered with global generics pharmaceuticals manufactures to provide Canadians with high quality and affordable generic drugs and OTC products.

The Company is lead by Mr. Arun Nayyar, an international generic pharmaceuticals executive with over 30 years of experience and a track record of achieving market penetration, sales channel development, product in-licensing and regulatory registration.

Vanc currently has a generic portfolio consisting of over 30 molecules, which represent both chronic and acute conditions. The Company also has four niche market OTC products covering the iron supplement (Feroheme), pediatric drops (Pedia-Safe), a natural laxative (Sennna-Lax) and cortisone ointment (T36 + 0.5% Hydrocortisone). The Company plans to launch sales in Q2-2015 and in February 2015 announced a LOI with a Western Canada based pharmacy chain to become a preferred supplier.